Acumen Pharmaceuticals Inc (ABOS) — Who's Buying and Selling (13F, Q2 2026)

ABOS ranks #4650 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

98 institutions disclose a position in ABOS, but none treat it as a major bet — even Sands Capital Alternatives, LLC, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Ra Capital Management, L.p. has added to its ABOS position for two straight quarters, increasing it by $24.5M to reach $56.1M today.

Fidelity has trimmed its ABOS position for two straight quarters, cutting it by $4.3M while still holding $20.1K.

ABOS is up 6.2% today, and institutions have been net buyers of $9.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ABOS reported a net loss of $121.3M in its latest fiscal year.

• Not yet profitable — net loss of $121.3M in the latest fiscal year
• Net income declined year over year, from -$102.3M to -$121.3M
• Operating cash flow was negative, using $115.5M in cash
• Current ratio of 4.07x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.74x equity — within a conventional range